We Want to Do Our Part: A Corporate Funder Steps up for Trans Communities

We Want to Do Our Part: A Corporate Funder Steps up for Trans Communities

Transgender communities face inordinate challenges, but receive a small slice of philanthropic funding. With a new grantmaking program that draws on input from the trans community, Gilead Sciences is helping to change that.

Read More

So Close, Yet So Far: Why is HIV/AIDS Funding Decreasing?

So Close, Yet So Far: Why is HIV/AIDS Funding Decreasing?

Nearly 1 million people die annually from HIV/AIDS, despite antiretroviral drugs that can extend their lives. And while the world’s billionaires sit on trillions of dollars, private donors are doing less to combat the epidemic. What’s going on here?

Read More

The Corporate Funder Giving New Attention to HIV/AIDS in the American South

The Corporate Funder Giving New Attention to HIV/AIDS in the American South

Gilead Sciences recently announced a 10-year, $100 million commitment to combat HIV/AIDS in the South—the latest funder to respond to a disturbingly high prevalence of infections in the region. 

Read More